In 2023, nearly 2 million people in the United States will be diagnosed with cancer. Approximately 300,000 will be women with breast cancer, making it the most common cancer diagnosis. For Lumicell, a MedTech company based in Newton, Massachusetts, this is personal. The founders were profoundly impacted by cancer. So, they set out to create […]
In 2023, nearly 2 million people in the United States will be diagnosed with cancer. Approximately 300,000 will be women with breast cancer, making it the most common cancer diagnosis. For Lumicell, a MedTech company based in Newton, Massachusetts, this is personal. The founders were profoundly impacted by cancer. So, they set out to create an innovative technology to help doctors and patients. The Lumicell Direct Visualization System is designed to assist surgeons in the identification of residual cancer as demonstrated in a successful pivotal trial.
As the company moved into the final stages of FDA approval, and its go-to-market implementation of the product, Return on Good was engaged to help spread the word to the next round of investors.
Return on Good’s help centered on several key components to amplify the next stage of investor outreach:
- Identification of potential investors using Return on Good’s proprietary list of prospects, including key contacts, area of passion, and recent investment
- Creation of an impact explainer video, outlining the groundbreaking Lumicell DVS technology succinctly, and the opportunity to impact the world for good.
- Development and execution of outreach campaign to invite potential investment partners to learn more through content, and next step discussions.
“This is the one-two-three punch that modern impact investment marketing requires – identifying the right potential investors, sharing with them an accurate picture of the opportunity, and making it easy for a company to follow up with those who are interested,” says Jay Kelly, Return on Good’s co-founder. And this combination is a game changer for a company that needs investment, but must remain focused on driving their product to approval and market.
“When you are busy doing all the things needed to create a life-saving medical technology, you have so much on your plate. Optimized investment outreach is key to continuing the pipeline of investors,” says Jay.
In today’s market with many options, a targeted, coordinated and impact-driven approach is crucial to capture the interest of passionate investors. To find out how this approach can help your project, or to connect with Return on Good’s curated portfolio of investment opportunities doing good in the world, contact us today